What Is Mazdutide? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Mazdutide is not FDA-approved in the United States. Products sold online as mazdutide, IBI362, LY3305677, GLP-1/glucagon peptides, or “research use only” mazdutide may carry serious safety, quality, legal, and regulatory risks.

Quick answer

Mazdutide is a once-weekly dual glucagon-like peptide-1 and glucagon receptor agonist. It is also known as IBI362 or LY3305677. Mazdutide was developed by Innovent Biologics and Eli Lilly and is designed to combine GLP-1 receptor effects, such as appetite reduction and glucose control, with glucagon receptor effects, such as increased energy expenditure and liver-fat-related metabolic effects. In 2025, mazdutide was approved in China for chronic weight management in adults with overweight or obesity and later for glycemic control in adults with type 2 diabetes. It is not FDA-approved in the United States. Clinical trials in Chinese adults show meaningful weight loss and HbA1c reduction, but U.S. approval, long-term cardiovascular outcomes, broad global safety data, and real-world durability remain important open questions.

Key facts about Mazdutide

What is mazdutide?

Mazdutide is a dual GLP-1 and glucagon receptor agonist. It is designed to activate two hormone receptor pathways involved in appetite, blood glucose, body weight, energy expenditure, and metabolic regulation.

Mazdutide is also known as:

• IBI362
• LY3305677

It was developed by Innovent Biologics through a collaboration with Eli Lilly. Innovent has commercial rights in China.

The New England Journal of Medicine phase 3 obesity trial describes mazdutide as a glucagon-like peptide-1 and glucagon receptor dual agonist studied in Chinese adults with overweight or obesity.

The Nature phase 3 type 2 diabetes trial describes mazdutide as a once-weekly glucagon and GLP-1 receptor dual agonist developed for type 2 diabetes.

The key distinction:

Mazdutide is not just another GLP-1. It is a dual GLP-1/glucagon receptor agonist. That makes it mechanistically different from semaglutide, liraglutide, and lixisenatide.

How does mazdutide work?

Mazdutide activates two receptor systems:

1. GLP-1 receptor
2. Glucagon receptor

The GLP-1 receptor side is associated with:

• Reduced appetite
• Increased satiety
• Slower gastric emptying
• Improved glucose-dependent insulin secretion
• Lower glucagon secretion in hyperglycemic states
• Better glycemic control

The glucagon receptor side is associated with:

• Increased energy expenditure
• Effects on liver metabolism
• Possible liver-fat reduction
• Possible lipid and cardiometabolic effects
• Additional weight-loss biology beyond GLP-1 alone

In plain English:

Mazdutide tries to combine appetite suppression and glucose control from GLP-1 activation with energy-expenditure and liver-metabolism effects from glucagon activation.

That is why it is often compared with semaglutide and tirzepatide, even though it is not the same type of drug.

The practical interpretation:

Mazdutide is a next-generation metabolic peptide drug candidate that sits between GLP-1-only drugs and triple agonists like retatrutide.

What is mazdutide used for?

Mazdutide is primarily studied and used for obesity, chronic weight management, and type 2 diabetes.

| Use | Evidence level | What is known | What is not known | |---|---|---| | Chronic weight management | Strong China phase 3 evidence | Mazdutide has phase 3 evidence and China NMPA approval for chronic weight management. | U.S. FDA approval and broad global real-world data are not established. | | Type 2 diabetes glycemic control | Strong China phase 3 evidence | Mazdutide has phase 3 evidence and China NMPA approval for glycemic control in adults with type 2 diabetes. | U.S. FDA approval and long-term comparative outcomes are not established. | | Weight loss in people with obesity | Strong evidence in Chinese trial populations | Phase 3 obesity data show clinically meaningful body-weight reductions. | Data across diverse global populations are still developing. | | Cardiometabolic markers | Moderate evidence | Trials report improvements in waist circumference and metabolic markers. | Long-term cardiovascular outcomes are not yet established. | | Liver fat / metabolic liver disease | Early to moderate research interest | Glucagon receptor activity may influence liver-fat metabolism. | It is not approved as a liver-disease drug. | | Anti-aging / longevity | Unsupported | Weight and metabolic improvement can affect health risk. | Mazdutide is not an anti-aging or longevity therapy. | | Bodybuilding / casual cutting | Unsupported and medically inappropriate | Appetite and weight effects may attract misuse. | It is not a bodybuilding drug. | | Online research-use mazdutide | High risk | Sellers may market GLP-1/glucagon peptides online. | Quality, sterility, identity, dose, and legality may be unknown. |

What does the research show?

Phase 3 obesity evidence

Mazdutide has strong phase 3 evidence for weight loss in Chinese adults with overweight or obesity.

The NEJM phase 3 trial studied once-weekly mazdutide at 4 mg and 6 mg doses for 32 weeks in Chinese adults with overweight or obesity. The trial reported clinically relevant body-weight reductions versus placebo.

The PubMed abstract of the same trial describes mazdutide as a GLP-1 and glucagon receptor dual agonist and summarizes the randomized trial design.

The practical interpretation:

Mazdutide has real late-stage obesity evidence, not just early hype. But its strongest public phase 3 obesity evidence is currently centered on Chinese trial populations.

Phase 3 type 2 diabetes evidence

Mazdutide also has phase 3 diabetes evidence.

A Nature phase 3 trial compared mazdutide with dulaglutide in Chinese adults with type 2 diabetes on background oral anti-diabetic drugs. The study randomized 731 participants to mazdutide 4 mg, mazdutide 6 mg, or dulaglutide 1.5 mg for 28 weeks.

A PubMed phase 3 placebo-controlled diabetes study reported HbA1c reductions at week 24 of -1.57% with mazdutide 4 mg and -2.15% with mazdutide 6 mg versus placebo.

The practical interpretation:

Mazdutide has credible diabetes efficacy data, especially for HbA1c reduction and weight reduction in adults with type 2 diabetes.

Head-to-head diabetes and obesity comparison research

Mazdutide is also being compared with established GLP-1 drugs.

A PubMed record for the DREAMS-3 phase 3 trial describes the rationale, design, and baseline data for a mazdutide versus semaglutide trial in type 2 diabetes and obesity.

A Reuters report reported that Innovent said mazdutide outperformed semaglutide in a late-stage Chinese diabetes and obesity trial, including greater average weight loss and HbA1c reduction. Because this is company-reported through news coverage, it should be treated as important but not the same as a full peer-reviewed publication.

The practical interpretation:

Mazdutide may become a serious competitor to semaglutide in China, but head-to-head claims should be judged by full peer-reviewed data, not press-release headlines alone.

Earlier phase evidence

Earlier studies support mazdutide’s biological and clinical development.

A PubMed phase 1b study reported that high-dose mazdutide showed promising 12-week weight-loss results in Chinese adults with obesity.

A PMC meta-analysis concluded that mazdutide produced significantly greater mean percentage weight loss than placebo across available trials.

A PMC review/meta-analysis reviewed mazdutide weight-loss evidence in adults with overweight or obesity.

The practical interpretation:

Mazdutide’s evidence base has moved beyond phase 1, but long-term outcomes, rare adverse events, cardiovascular outcomes, and global generalizability are still developing.

China approval status

Mazdutide is approved in China.

Innovent announced that China’s National Medical Products Administration approved mazdutide for chronic weight management in adults with overweight or obesity on June 27, 2025.

Innovent later announced that China’s NMPA approved mazdutide for glycemic control in adults with type 2 diabetes on September 19, 2025.

The practical interpretation:

Mazdutide is not merely investigational everywhere. It has reached the market in China. But China approval is not the same as U.S. FDA approval.

Evidence summary

Is mazdutide FDA-approved?

No. Mazdutide is not FDA-approved in the United States.

There is no FDA-approved mazdutide product for obesity, type 2 diabetes, weight loss, body recomposition, fatty liver disease, anti-aging, or any other use.

The FDA has also warned broadly about illegal or unverified GLP-1 drug ingredients. The FDA announcement on its GLP-1 “green list” import alert says the agency is working to stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market.

The key distinction:

Approved mazdutide in China is not the same as an FDA-approved U.S. medication, and online “research use” mazdutide is not the same as a regulated prescription product.

Is mazdutide legal?

Mazdutide’s legal status depends on country, product type, prescription status, and intended use.

In China, mazdutide has received NMPA approval for specific indications. In the United States, mazdutide is not FDA-approved.

The practical answer for U.S. readers:

Mazdutide is not an FDA-approved drug in the U.S., and online availability does not mean it is legally marketed for human therapeutic use.

The blunt version:

Buying “research use only” mazdutide online is not the same as receiving an approved GLP-1 medication from a legitimate pharmacy.

Is mazdutide banned in sports?

Mazdutide is a GLP-1/glucagon receptor dual agonist. Anti-doping status should be checked through official resources because drug classes can change.

The USADA GLP-1 athlete guide says GLP-1 drugs are not currently prohibited in sport, but WADA is monitoring and evaluating GLP-1 agonist use by athletes.

The WADA GLP-1 receptor agonist monitoring research page discusses monitoring of GLP-1 receptor agonists including semaglutide and liraglutide.

The practical advice:

Mazdutide should not automatically be assumed safe for athletes. GLP-1 drugs are being monitored, mazdutide also has glucagon receptor activity, and athletes should verify current status through Global DRO, WADA, or USADA before use.

Safety and side effects

Mazdutide has real pharmacologic activity. It should not be treated like a harmless supplement.

Common or likely side effects, based on mazdutide trials and incretin-drug class patterns, may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite
• Abdominal discomfort
• Dyspepsia
• Dizziness
• Injection-site reactions
• Possible gallbladder-related issues
• Possible pancreatitis-related concerns by class analogy
• Possible dehydration risk from severe vomiting or diarrhea
• Possible hypoglycemia risk when combined with insulin or insulin secretagogues
• Unknown long-term cardiovascular outcomes
• Unknown long-term rare adverse-event profile across diverse populations

The glucagon receptor activity matters.

Glucagon receptor agonism may contribute to weight loss and metabolic effects, but it may also introduce different safety considerations than GLP-1-only drugs. That is why mazdutide should not be lazily described as “basically Ozempic.”

A serious evaluation of mazdutide should separate:

Mazdutide vs similar drugs and peptides

The key distinction:

Mazdutide belongs in the GLP-1/glucagon dual-agonist category. It is not a GLP-1-only drug, not a GIP/GLP-1 drug, not an amylin analog, and not a generic peptide supplement.

Why is mazdutide sold as “research use only”?

Some online sellers may use “research use only” language to sell mazdutide or mazdutide-like peptides outside normal prescription channels.

That label is not a trust signal.

A serious reader should understand this distinction:

How to evaluate mazdutide claims online

Bottom line

Mazdutide is a once-weekly dual GLP-1 and glucagon receptor agonist with strong emerging evidence for weight loss and glycemic control in Chinese clinical trials. It is approved in China for chronic weight management and for glycemic control in adults with type 2 diabetes.

The most defensible conclusion is:

Mazdutide is a serious next-generation metabolic drug, not a casual research peptide. It is not FDA-approved in the United States, and readers should distinguish regulated China-approved mazdutide from unapproved online mazdutide products with uncertain identity, purity, sterility, and legal status.

FAQ

What is mazdutide?

Mazdutide is a once-weekly dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics and Eli Lilly. It is also known as IBI362 or LY3305677.

What does mazdutide do?

Mazdutide activates GLP-1 receptors and glucagon receptors. It is designed to reduce appetite, improve glucose control, support weight loss, and influence energy expenditure and metabolic pathways.

Is mazdutide FDA-approved?

No. Mazdutide is not FDA-approved in the United States.

Is mazdutide approved in China?

Yes. Mazdutide has been approved by China’s NMPA for chronic weight management and for glycemic control in adults with type 2 diabetes.

Is mazdutide the same as Ozempic?

No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Mazdutide is a dual GLP-1 and glucagon receptor agonist.

Is mazdutide the same as Mounjaro?

No. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Mazdutide targets GLP-1 and glucagon receptors.

Is mazdutide the same as retatrutide?

No. Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist. Mazdutide is a dual GLP-1 and glucagon receptor agonist.

Does mazdutide cause weight loss?

Yes, clinical trials show that mazdutide can produce clinically meaningful weight loss in adults with overweight or obesity. It is approved in China for chronic weight management.

Does mazdutide help type 2 diabetes?

Yes, clinical trials show that mazdutide can reduce HbA1c and body weight in adults with type 2 diabetes. It is approved in China for glycemic control in adults with type 2 diabetes.

Is mazdutide better than semaglutide?

Not enough public, peer-reviewed head-to-head evidence is available to make a broad global conclusion. Company-reported China trial data suggest strong results, but full peer-reviewed comparisons matter.

Is mazdutide safe?

Mazdutide has clinical-trial safety data, but it is not risk-free. Common concerns include gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, and appetite loss. Long-term cardiovascular outcomes and broader real-world safety data are still developing.

Is mazdutide legal in the U.S.?

Mazdutide is not FDA-approved in the U.S. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.

Is mazdutide banned in sports?

GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Because mazdutide also activates glucagon receptors, athletes should verify current status through WADA, USADA, or Global DRO before use.

Why do sellers call mazdutide “research use only”?

Sellers often use “research use only” language because mazdutide is not FDA-approved for consumer therapeutic use in the U.S. The phrase does not make the product safe, legal, approved, or clinically proven.

What is the biggest risk with mazdutide?

The biggest risks are using an unapproved metabolic drug without medical supervision, confusing China-approved regulated products with online research-use peptides, and buying products with uncertain identity, purity, sterility, concentration, and safety.

Sources

1. NEJM: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
2. PubMed: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
3. Nature: Mazdutide versus Dulaglutide in Chinese Adults with Type 2 Diabetes
4. PubMed: Mazdutide versus Placebo in Chinese Adults with Type 2 Diabetes
5. PubMed: Mazdutide versus Semaglutide DREAMS-3 Phase 3 Trial Design
6. PubMed: Safety and Efficacy of Mazdutide 9 mg and 10 mg in Chinese Adults with Overweight or Obesity
7. PMC: Efficacy and Safety of Mazdutide on Weight Loss Among Patients with Overweight or Obesity
8. PMC: Mazdutide Reduces Body Weight in Adults with Overweight or Obesity
9. Innovent: Mazdutide Received Approval from China’s NMPA for Chronic Weight Management
10. Innovent: Mazdutide Received Approval from China’s NMPA for Glycemic Control in Adults with Type 2 Diabetes
11. Shanghai Government: Weight Loss Medicine Mazdutide Approved for Chronic Weight Management
12. Reuters: Innovent Says Mazdutide Outperformed Semaglutide in China Diabetes Study
13. FDA: Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
14. USADA: Weight Loss Drugs, What Athletes Need to Know About GLP-1s
15. WADA: GLP-1 Receptor Agonists Monitoring Research